New Patient-Oriented Tools for Assessing Atrophic Acne Scarring

Layton, Alison; Dréno, Brigitte; Finlay, Andrew Y.; Thiboutot, Diane; Kang, Sewon; Lozada, Vicente Torres; Bourdès, Valérie; Bettoli, Vincenzo; Petit, Laurent; Tan, Jerry

doi:10.1007/s13555-016-0098-5

Cited by 22 publications

(28 citation statements)

References 15 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…69,70 QOL combined with other clinical measurements could be utilised as a gold standard in additional conditions such as psoriasis, acne, and rosacea. 71-73…”

Section: Treatment Goalsmentioning

confidence: 99%

“…69,70 QOL combined with other clinical measurements could be utilised as a gold standard in additional conditions such as psoriasis, acne, and rosacea. [71][72][73] A 5-mm outgrowth of healthy nail is the recommended FDA definition of a pharmacotherapy responder with an adjusted definition for medical devices, yielding >6 mm of clear nail, an additional 60 mm 2 of clear nail, or complete clearance 6 months after their first laser treatment. 4 Many recent articles have suggested that follow-up periods for all therapies should be increased to reflect toenail growth, increasing follow-up periods to 12 to 18 months posttreatment rather than the current customary 4-week follow-up duration.…”

Section: Suggested End Pointsmentioning

confidence: 99%

See 1 more Smart Citation

Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment

2017

View full text Add to dashboard Cite

Onychomycosis accounts for 50% of all nail disease cases and is commonly caused by dermatophytes. Diabetes, human immunodeficiency virus, immunosuppression, obesity, smoking, and advancing age are predisposing factors of this fungal infection. Potassium hydroxide and culture are considered the current standard for diagnosing onychomycosis, revealing both fungal viability and species identification. Other diagnostic tests currently available include periodic acid-Schiff staining, polymerase chain reaction techniques, and fluorescent staining. Across 6 recently published epidemiology studies, the global prevalence of onychomycosis was estimated to be 5.5%, falling within the range of previously reported estimates (2%-8%). Newly approved onychomycosis treatments include efinaconazole, tavaborole, and laser therapy with lasers only approved to temporarily increase the amount of clear nail. Additional onychomycosis treatments being investigated include iontophoresis and photodynamic therapy with small open-label studies reported thus far. Preventative strategies, to help decrease recurrence and reinfection rates, include sanitisation of footwear and prophylactic topical antifungal agents.

show abstract

“…69,70 QOL combined with other clinical measurements could be utilised as a gold standard in additional conditions such as psoriasis, acne, and rosacea. 71-73…”

Section: Treatment Goalsmentioning

confidence: 99%

Section: Suggested End Pointsmentioning

confidence: 99%

Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment

2017

View full text Add to dashboard Cite

show abstract

“…The ACNE‐Q differs from other available acne‐specific PROMs by comprehensively addressing appearance (of facial skin, face, chest and back acne, and acne scars) in addition to appearance‐related distress and symptoms. Only the five‐item SCARS scale covers the appearance construct in depth by including items asking about coverage, number, size, depth and visibility of acne scars . The ACNE‐Q scar scale covers these issues, and also includes items that ask about the appearance of scars in different scenarios (e.g.…”

Section: Discussionmentioning

confidence: 99%

“…Authors of a 2018 literature review of PROMs used in acne identified eight acne‐specific measures: the 21‐item Acne Quality of Life Index; the 19‐item Acne‐Specific Quality of Life Questionnaire; the four‐item Acne‐Q4; the 15‐item Assessment of the Psychological and Social Effects of Acne; the 10‐item Acne Disability Index; the five‐item Cardiff Acne Disability Index; the nine‐item Acne Quality of Life; and the 17‐item Acne Symptom and Impact Scale . Instruments not captured in the review include the 20‐item Comprehensive Acne Quality of Life (CompAQ), and two instruments for which only the concept elicitation findings were published: the 10‐item facial acne scar quality of life (FasQoL) and the five‐item self‐assessment of clinical acne‐related scars (SCARS) . Three of these 11 PROMs are specific to facial acne; six are designed for acne in specific locations; and two are scar‐specific .…”

mentioning

confidence: 99%

“…Instruments not captured in the review include the 20‐item Comprehensive Acne Quality of Life (CompAQ), and two instruments for which only the concept elicitation findings were published: the 10‐item facial acne scar quality of life (FasQoL) and the five‐item self‐assessment of clinical acne‐related scars (SCARS) . Three of these 11 PROMs are specific to facial acne; six are designed for acne in specific locations; and two are scar‐specific . These PROMS have a total of 135 items of which 77·8% are in scales that measure psychosocial concerns (e.g.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Development of a new patient‐reported outcome measure to evaluate treatments for acne and acne scarring: the ACNE ‐Q

Klassen

Lipner

O'Malley³

et al. 2019

Br J Dermatol

View full text Add to dashboard Cite

Summary Background Psychosocial concerns represent important outcomes in studies of treatments for acne and acne scarring. Also important, but largely overlooked, is the concept of appearance. Objectives To design an acne‐specific patient‐reported outcome measure for acne and acne scarring. Methods We used a mixed‐methods approach. Phase I involved 21 patient interviews that were audio‐recorded, transcribed and coded. Concepts were identified and developed into scales that were refined through 10 cognitive interviews and input from 16 clinical experts. Phase II involved data collection at hospital and community‐based dermatology clinics in Canada and the U.S.A. Eligible participants were aged 12 years and older with acne and/or acne scars on the face, chest and/or back. Rasch Measurement Theory (RMT) analyses were performed to examine psychometric properties. Results Phase I led to the development of seven scales that measure appearance of facial skin, acne (face, chest and back) and acne scars, acne‐specific symptoms and appearance‐related distress. In phase II, 256 patients completed the ACNE‐Q. RMT analysis provided evidence that the items of each scale worked together conceptually and statistically. Most participants scored within the range of measurement for each scale (81·9–93·1%). Reliability was high, with person separation index values and Cronbach alpha values > 0·90 for the appearance scales, ≥ 0·87 for appearance‐related distress and ≥ 0·75 for symptoms. Worse scores on appearance scales correlated with worse symptom scores and more appearance‐related distress. Conclusions The ACNE‐Q is a rigorously developed instrument that can be used to measure appearance and other patient‐centred concerns. What's already known about this topic? Acne is a common dermatological condition that can have an important impact on psychosocial function. Current patient‐reported outcome measures specific to acne focus mostly on measuring psychological and social impact. What does this study add? The ACNE‐Q provides a set of independently functioning scales that measure appearance of facial, back and chest acne, acne scarring and facial skin. Additional scales measure appearance‐related distress and acne symptoms. What are the clinical implications of this work? ACNE‐Q provides the dermatology community with a rigorously developed patient‐reported measure for acne that can be applied in clinical trials, research and patient care. The measurement of appearance by ACNE‐Q scales is more comprehensive than in other instruments providing important information on appearance of their acne and/or acne scars from the patient perspective.

show abstract

Principles of Measurement and Assessment in Dermatology

Finlay,

Ali

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

This chapter describes why it is important to measure the severity of skin disease, what can and should be measured, who should do the measuring and how to interpret scores. The validation of measures is explained, including by electronic delivery. The concept of core outcomes is described, as are the clinical assessment tools used across the main inflammatory skin diseases. Many objective methods for measuring skin disease are being developed. The measurement of the impact of skin disease can be assessed by using a range of different quality of life measures, usually questionnaires, including disease specific, dermatology specific and generic measures that can also be used across medicine. Most measures are designed for use in adults, but there are separate questionnaires for use in specific age ranges such as children and adolescents. Skin disease can have a major secondary impact on the quality of life of partners and other family members: this impact is assessed by a parallel range of disease specific, dermatology specific or generic measures. There are also methods to measure the impact of skin disease on psychological health, on sexual functioning and on ability to work.

show abstract

New Patient-Oriented Tools for Assessing Atrophic Acne Scarring

Cited by 22 publications

References 15 publications

Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment

Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment

Development of a new patient‐reported outcome measure to evaluate treatments for acne and acne scarring: the ACNE ‐Q

Principles of Measurement and Assessment in Dermatology

Contact Info

Product

Resources

About